Skip to main content

Table 1 Characteristics of pulmonary tuberculosis (PTB) patients with different recurrence frequency, Henan province, 2005–2018

From: Epidemiology of recurrent pulmonary tuberculosis by bacteriological features of 100 million residents in China

Characteristic

No recurrence (n = 961,809)

Recurrence PTB

Primary onset (n = 7143)

Recurrence 1 (n = 6739)

Recurrence 2 (n = 379)

Recurrence ≥ 3 (n = 25)

Sex

 Male

676,648 (70.4)

5505 (77.1)

5505 (77.2)

313 (77.8)

18 (72.0)

 Female

285,161 (29.6)

1638 (22.9)

1638 (22.8)

91 (22.2)

9 (28.0)

Median (IQR)

48 (28–63)

54 (40–64)

57 (42–67)

59 (48–68)

63 (54–68)

Age group (years)

 0–14

9407 (1.0)

22 (0.3)

5 (0.1)

0 (0.0)

0 (0.0)

 15–29

246,098 (25.6)

1198 (16.8)

993 (14.7)

35 (9.2)

3 (12.0)

 30–44

180,552 (18.8)

1065 (14.9)

912 (13.5)

39 (10.3)

0 (0.0)

 45–59

218,838 (22.8)

2150 (30.1)

1819 (27.0)

118 (31.1)

7 (28.0)

 ≥ 60

306,504 (31.9)

2708 (37.9)

3010 (44.7)

187 (49.3)

15 (60.0)

 Unknown

410 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Median of time delay (days, range)

 Time from onset to first hospital visit

13 (2–30)

11 (1–31)

11 (1–30)

12 (1–31)

2 (0–16)

 Time from onset to confirm

23 (10–40)

14 (30–59)

27 (14–44)

31 (16–50)

28 (17–36)

 Time from onset to course end

208 (192–234)

215 (198–249)

223 (200–274)

240 (203–284)

220 (207–255)

 Time from hospitalization to course end

185 (182–198)

189 (184–215)

199 (183–249)

210 (184–258)

211 (191–246)

Management mode

 Enhanced supervision

479,607 (49.9)

3624 (50.7)

3733 (55.4)

198 (52.2)

11 (44.0)

 DOTS

450,977 (46.9)

3511 (49.2)

2922 (43.4)

175 (46.2)

13 (52.0)

 Self-medication

8119 (0.8)

7 (0.1)

12 (0.2)

3 (0.8)

1 (4.0)

 Unknown

23,106 (2.4)

1 (0.0)

72 (1.1)

3 (0.8)

0 (0.0)

Outcome

 Cured

292,466 (30.4)

3212 (45.0)

1749 (26.0)

85 (22.4)

5 (20.0)

 Treatment completed

483,794 (50.3)

3931 (55.0)

3783 (56.1)

208 (54.9)

15 (60.0)

 Death

8112 (0.8)

0 (0.0)

92 (1.4)

7 (1.9)

1 (4.0)

 Unknown

177,437 (18.4)

0 (0.0)

1115 (16.6)

79 (20.8)

4 (16.0)

  1. Data are presented as n (%) of patients unless otherwise indicated
  2. DOTS directly observed treatment short course chemotherapy, IQR interquartile range